PL2875016T3 - Pochodne karbaminianowe/mocznikowe - Google Patents

Pochodne karbaminianowe/mocznikowe

Info

Publication number
PL2875016T3
PL2875016T3 PL13770709T PL13770709T PL2875016T3 PL 2875016 T3 PL2875016 T3 PL 2875016T3 PL 13770709 T PL13770709 T PL 13770709T PL 13770709 T PL13770709 T PL 13770709T PL 2875016 T3 PL2875016 T3 PL 2875016T3
Authority
PL
Poland
Prior art keywords
carbamate
urea derivatives
urea
derivatives
Prior art date
Application number
PL13770709T
Other languages
English (en)
Polish (pl)
Inventor
Yves Auberson
Mark Gary Bock
Dario Braga
Marco Curzi
Stephanie Kay Dodd
Stefano Luca Giaffreda
Haiyang Jiang
Piotr Karpinski
Thomas J Troxler
Tielin Wang
Xiaoyang Wang
Xuechun Zhang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49263333&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2875016(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL2875016T3 publication Critical patent/PL2875016T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13Dicarboxylic acids
    • C07C57/15Fumaric acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235Saturated compounds containing more than one carboxyl group
    • C07C59/245Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265Citric acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL13770709T 2012-07-20 2013-07-18 Pochodne karbaminianowe/mocznikowe PL2875016T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2012078933 2012-07-20
CN2013078309 2013-06-28
PCT/IB2013/055916 WO2014013469A1 (en) 2012-07-20 2013-07-18 Carbamate/urea derivatives
EP13770709.7A EP2875016B1 (en) 2012-07-20 2013-07-18 Carbamate/urea derivatives

Publications (1)

Publication Number Publication Date
PL2875016T3 true PL2875016T3 (pl) 2018-01-31

Family

ID=49263333

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13770709T PL2875016T3 (pl) 2012-07-20 2013-07-18 Pochodne karbaminianowe/mocznikowe

Country Status (41)

Country Link
US (4) US9034874B2 (OSRAM)
EP (1) EP2875016B1 (OSRAM)
JP (1) JP6203841B2 (OSRAM)
KR (1) KR102150739B1 (OSRAM)
CN (1) CN104470911B (OSRAM)
AP (1) AP3710A (OSRAM)
AR (1) AR092354A1 (OSRAM)
AU (1) AU2013291617B2 (OSRAM)
BR (1) BR112015001207B1 (OSRAM)
CA (1) CA2878006C (OSRAM)
CL (1) CL2015000056A1 (OSRAM)
CO (1) CO7170173A2 (OSRAM)
CR (1) CR20150019A (OSRAM)
CU (1) CU24248B1 (OSRAM)
CY (1) CY1119492T1 (OSRAM)
DK (1) DK2875016T3 (OSRAM)
EA (1) EA026091B1 (OSRAM)
ES (1) ES2648512T3 (OSRAM)
GT (1) GT201500012A (OSRAM)
HR (1) HRP20171692T1 (OSRAM)
HU (1) HUE035592T2 (OSRAM)
IL (1) IL236656A (OSRAM)
IN (1) IN2014DN10449A (OSRAM)
JO (1) JO3439B1 (OSRAM)
LT (1) LT2875016T (OSRAM)
MX (1) MX362059B (OSRAM)
MY (1) MY168752A (OSRAM)
NO (1) NO2875016T3 (OSRAM)
NZ (1) NZ702346A (OSRAM)
PE (1) PE20151155A1 (OSRAM)
PH (1) PH12014502743B1 (OSRAM)
PL (1) PL2875016T3 (OSRAM)
PT (1) PT2875016T (OSRAM)
RS (1) RS56479B1 (OSRAM)
SG (2) SG10201700188PA (OSRAM)
SI (1) SI2875016T1 (OSRAM)
TN (1) TN2014000497A1 (OSRAM)
TW (1) TWI597276B (OSRAM)
UY (1) UY34921A (OSRAM)
WO (1) WO2014013469A1 (OSRAM)
ZA (1) ZA201408805B (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR088256A1 (es) 2011-10-08 2014-05-21 Novartis Ag Derivados de carbamato / urea como antagonistas del receptor h3
US9034874B2 (en) 2012-07-20 2015-05-19 Novartis Ag Carbamate/urea derivatives
EP3391886A1 (en) 2017-04-19 2018-10-24 Novartis AG The use of a h3r inverse agonist for the treatment of shift work disorder
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
KR20210075084A (ko) 2018-10-11 2021-06-22 노파르티스 아게 파킨슨병(pd)과 관련된 주간 수면과다증의 치료를 위한 h3r 역효능제의 용도
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
WO2022113008A1 (en) 2020-11-27 2022-06-02 Richter Gedeon Nyrt. Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2567518B1 (fr) 1984-07-11 1987-11-13 Sanofi Sa Nouveaux composes a noyau heterocyclique azote, leur preparation et les medicaments qui en contiennent
TW301607B (OSRAM) 1993-03-09 1997-04-01 Takeda Pharm Industry Co Ltd
KR20020080378A (ko) * 2000-01-20 2002-10-23 에자이 가부시키가이샤 신규 피페리딘 화합물 및 그의 의약
AU2002244271A1 (en) 2001-03-13 2002-09-24 Pharmacopeia, Inc. Non-imidazole compounds as histamine h3 antagonists
EP1631260A2 (en) 2003-02-28 2006-03-08 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
WO2004101546A1 (en) 2003-04-23 2004-11-25 Glaxo Group Limited Piperazine derivatives and their use for the treatment of neurological and psychiatric diseases
CA2555824C (en) 2004-02-13 2011-06-07 Banyu Pharmaceutical Co., Ltd. Fused-ring 4-oxopyrimidine derivative
SE0401971D0 (sv) 2004-08-02 2004-08-02 Astrazeneca Ab Piperidne derivatives
US20060074117A1 (en) 2004-09-02 2006-04-06 Lilach Hedvati Purification of olmesartan medoxomil
JP4511550B2 (ja) 2004-09-02 2010-07-28 テバ ファーマシューティカル インダストリーズ リミティド オルメサルタンメドキソミルの調製法
EP1909797A4 (en) * 2005-08-02 2013-02-27 Neurogen Corp DIPIPERAZINYL KETONE AND RELATED ANALOG
EP1945639A1 (en) 2005-11-04 2008-07-23 Pfizer Limited Tetrahydronaphthyridine derivative
EP1970373A1 (en) 2005-12-02 2008-09-17 Mitsubishi Tanabe Pharma Corporation Alicyclic heterocyclic compound
AU2008333183A1 (en) * 2007-12-05 2009-06-11 Astrazeneca Ab (Publ) Piperazine derivatives and their use as leptin receptor modulators
TWI498115B (zh) * 2007-12-27 2015-09-01 Daiichi Sankyo Co Ltd 咪唑羰基化合物
EP2328586A2 (en) 2008-05-20 2011-06-08 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
ES2601007T3 (es) 2010-01-22 2017-02-13 Taiho Pharmaceutical Co., Ltd. Compuesto de piperazina que presenta un efecto inhibidor de PGDS
TW201217312A (en) * 2010-09-22 2012-05-01 Gruenenthal Gmbh Substituted benzamide compounds
AR088256A1 (es) * 2011-10-08 2014-05-21 Novartis Ag Derivados de carbamato / urea como antagonistas del receptor h3
US9034874B2 (en) * 2012-07-20 2015-05-19 Novartis Ag Carbamate/urea derivatives

Also Published As

Publication number Publication date
EP2875016B1 (en) 2017-08-23
US20160244426A1 (en) 2016-08-25
JP6203841B2 (ja) 2017-09-27
KR102150739B1 (ko) 2020-09-02
IL236656A0 (en) 2015-02-26
DK2875016T3 (da) 2017-11-27
WO2014013469A1 (en) 2014-01-23
US9273026B2 (en) 2016-03-01
PH12014502743A1 (en) 2015-02-02
US9624192B2 (en) 2017-04-18
CA2878006A1 (en) 2014-01-23
EP2875016A1 (en) 2015-05-27
MY168752A (en) 2018-11-30
SI2875016T1 (sl) 2017-11-30
GT201500012A (es) 2017-11-09
EA026091B1 (ru) 2017-02-28
NO2875016T3 (OSRAM) 2018-01-20
CU24248B1 (es) 2017-02-02
HK1204609A1 (en) 2015-11-27
HUE035592T2 (en) 2018-05-28
AU2013291617B2 (en) 2015-10-01
CR20150019A (es) 2015-05-04
IN2014DN10449A (OSRAM) 2015-08-21
SG10201700188PA (en) 2017-02-27
AR092354A1 (es) 2015-04-15
ES2648512T3 (es) 2018-01-03
BR112015001207B1 (pt) 2022-08-09
PT2875016T (pt) 2017-11-30
US20140163036A1 (en) 2014-06-12
UY34921A (es) 2014-02-28
MX362059B (es) 2019-01-07
CN104470911A (zh) 2015-03-25
TW201408656A (zh) 2014-03-01
LT2875016T (lt) 2017-11-10
CY1119492T1 (el) 2018-03-07
JP2015522606A (ja) 2015-08-06
NZ702346A (en) 2017-06-30
CO7170173A2 (es) 2015-01-28
CA2878006C (en) 2020-10-27
IL236656A (en) 2017-12-31
KR20150036081A (ko) 2015-04-07
TWI597276B (zh) 2017-09-01
CL2015000056A1 (es) 2015-03-20
MX2015000903A (es) 2015-04-10
BR112015001207A8 (pt) 2018-01-16
US9034874B2 (en) 2015-05-19
AP3710A (en) 2016-05-31
BR112015001207A2 (pt) 2017-08-01
AU2013291617A1 (en) 2015-01-15
AP2014008109A0 (en) 2014-12-31
RS56479B1 (sr) 2018-01-31
HRP20171692T1 (hr) 2017-12-15
CU20150006A7 (es) 2016-02-29
SG11201408020RA (en) 2015-03-30
PE20151155A1 (es) 2015-08-05
EA201590250A1 (ru) 2015-05-29
PH12014502743B1 (en) 2015-02-02
CN104470911B (zh) 2018-04-06
TN2014000497A1 (en) 2016-03-30
US20170275264A1 (en) 2017-09-28
JO3439B1 (ar) 2019-10-20
US20150218127A1 (en) 2015-08-06
ZA201408805B (en) 2016-08-31

Similar Documents

Publication Publication Date Title
IL233476A0 (en) Carbamate compounds and their production and use
ZA201409422B (en) Benzimidazole-proline derivatives
ZA201408876B (en) Pyrrolotriazinone derivatives
AP3710A (en) Carbamate/urea derivatives
ZA201502175B (en) Oxazolidin-2-one-pyrimidine derivatives
PT2838883T (pt) Novos derivados de fenil-tetra-hidroisoquinolina
EP2794569A4 (en) HETEROCYCLIC UREA COMPOUNDS
SG11201404325VA (en) Pyrimidooxazocine derivatives as mtor - inhibitors
EP2854820A4 (en) DERIVATIVES OF 7- (PHENYL DISUBSTITUTED) -TETTRACYCLINE
GB201201616D0 (en) Transceiver
GB201202479D0 (en) Alternative pocket fastening
GB201212457D0 (en) Smart-road-smart-smart-vehicle synergy